Speaker illustration

Doctor Janet Leeds

South San Francisco (United States of America)

Physiologically-based pharmacokinetic (PBPK) model predicted versus observed effect of Child Pugh mild and moderate hepatic impairment on betrixaban pharmacokinetics

Event: ESC Congress 2018

Topic: Anticoagulants

Session: Optimal surrogate endpoints of drug response


Analysis of patient characteristics as covariates potentially affecting pharmacokinetics, efficacy, or safety of betrixaban in the APEX study

Event: ESC Congress 2017

Topic: Primary cardiovascular prevention: interventions and outcomes

Session: Best Posters in prevention, interventions and outcomes


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb